Filing Details

Accession Number:
0000904454-18-000644
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-04 20:59:04
Reporting Period:
2018-10-02
Accepted Time:
2018-10-04 20:59:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178711 Paratek Pharmaceuticals Inc. PRTK Pharmaceutical Preparations (2834) 330960223
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1628880 W. Douglas Pagan C/O Paratek Pharmaceuticals, Inc.
75 Park Plaza, 4Th Floor
Boston MA 02116
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-10-02 22,500 $0.00 99,583 No 4 A Direct
Common Stock Acquisiton 2018-10-02 27,500 $0.00 127,083 No 4 A Direct
Common Stock Disposition 2018-10-03 7,579 $9.82 119,504 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 S Direct
Footnotes
  1. Represents performance-based restricted stock units ("PRSUs") granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018.
  2. Represents PRSUs granted on August 3, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018. These PRSUs will settle in shares of common stock on October 2, 2019, provided that the Reporting Person remains in continuous service with Paratek Pharmaceuticals, Inc. through the settlement date.
  3. Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan.
  4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.75 to $9.95. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 to this Form 4.